Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

MNPR holding history

Monopar Therapeutics in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

MNPR overviewAll 13F holders of MNPRFull Q2 2026 holdings

Shares (Q2 2026)
27,259
Value
$2.52M
% of portfolio
<0.1%
Quarters held
18
Since Q1 2021
Holdings of MNPR by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202627,259$2.52M<0.1%−12,177−30.9%ReducedHolders
Q1 202639,436$2.16M<0.1%+35,186+827.9%AddedHolders
Q4 20254,250$277.5K<0.1%−3,723−46.7%ReducedHolders
Q3 20257,973$651.2K<0.1%−13,900−63.5%ReducedHolders
Q2 202521,873$782.6K<0.1%+13,752+169.3%AddedHolders
Q1 20258,121$295.7K<0.1%+1,698+26.4%AddedHolders
Q4 20246,423$141.3K<0.1%+5,911+1,154.5%AddedHolders
Q3 2024512$3.45K<0.1%+512NewHolders
Q2 20240$00.0%−2,568−100.0%Sold outHolders
Q1 20242,568$1.75K<0.1%−9,331−78.4%ReducedHolders
Q4 202311,899$4.05K<0.1%+11,827+16,426.4%AddedHolders
Q3 202372$45<0.1%+72NewHolders
Q2 20230$00.0%−6,388−100.0%Sold outHolders
Q1 20236,388$8.88K<0.1%+3,234+102.5%AddedHolders
Q4 20223,154$7.47K<0.1%−2,245−41.6%ReducedHolders
Q3 20225,399$8.00K<0.1%−14,162−72.4%ReducedHolders
Q2 202219,561$45.0K<0.1%+16,455+529.8%AddedHolders
Q1 20223,106$8.00K<0.1%+39+1.3%AddedHolders
Q4 20213,067$10.0K<0.1%+3,067NewHolders
Q2 20210$00.0%−571−100.0%Sold outHolders
Q1 2021571$4.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.